GenSight Biologics S.A.: GenSight Biologics Provides Update on LUMEVOQ Manufacturing and Commercialization Timelines

PPQ campaign to start early May 2023 (previously end of March) with results expected in Q3 2023 EMA CHMP opinion now expected in Q1 2024 (previously September 2023) Regulatory News: GenSight

Related Keywords

United States ,Paris ,France General ,France ,Dennis Riedl ,Clothilde Caillet ,James Palmer ,Gensight Biologics Euronext ,Guillaume Van Renterghem ,Jeanene Timberlake ,Gensight Biologics ,Brammer Bio ,Bernard Gilly ,Corporate Communications ,European Medicines Agency ,Drug Administration ,Manufacturing Sciences ,Sight Biologics ,Leber Hereditary Optic Neuropathy ,Thermo Fisher Scientific ,Good Manufacturing Practices ,Process Performance Qualification ,Manufacturing Operations ,Chief Executive Officer ,Early Access Authorisation ,European Committee ,Medicinal Products ,Human Use ,Sight Biologic ,Mitochondrial Targeting Sequence ,Gensight Biologic ,Institut De La Vision ,Adeno Associated Virus ,Communications Director ,Gensight ,Iologics ,Rovides ,Update ,Umevoq ,Manufacturing ,Ommercialization ,Timelines ,